GlioZERO · Advanced technologies for zeroing in on high-grade gliomas
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-03-01 → 2030-02-28
- Финансиране от ЕС
- 791 580 €
- Участници
- 11
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Глиобластомите са агресивни тумори в мозъка, които се изследват чрез нови полимерни филми за доставка на лекарства и AI-изобразяване при операциите. Това е важно, за да се преодолеят биологичните бариери на организма и да се подобрят терапиите при този вид рак.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Despite advances in diagnosis and therapy, glioblastoma (GBM) remains one of the most challenging cancers to treat, with overall survival under two years and a five-year survival rate of just 5%. This poor prognosis stems from three key factors: anatomical barriers, biological heterogeneity, immunosuppressive tumor microenvironment (TME).GlioZERO will establish a network of scientists with expertise in drug delivery, immunology, neurosurgery, robotics, and computational sciences to design microstructured polymeric films (microGRID) enabling deep, uniform, and sustained release of various therapeutic agents at the tumor margins; assess the efficacy of multimodal therapies in rigorous GBM models, leveraging microGRID to overcome anatomical barriers and systemic toxicity; improve surgical resection through intraoperative AI-assisted imaging; and employ advanced biological mapping to identify post-surgical TME alterations driving recurrence.To achieve these objectives, GlioZERO will bring together two EU Research Institutions, specialized in drug delivery, robotics, imaging (IIT) and brain cancer biology (Curie); two EU Enterprises, with expertise in neurosurgery (HUM) and computational modeling (BioIRC); four world-renowned US institutions advancing various therapies against GBM, including targeted therapies and immunotherapies (Stanford), oncolytic viruses (MD Anderson), anti-epileptic therapies (UCSF), and image-guided surgical therapies (BWH); and a Japanese partner (KU), focused on nano-therapies. Through interdisciplinary, intersectoral, and international secondments, GlioZERO will train a new generation of EU scientists, develop a novel class of drug delivery systems, and identify more effective therapies against GBM. Finally, partnerships with biotech accelerators in Silicon Valley, the Texas Medical Center, and the Greater Boston area will instill an entrepreneurial mindset and accelerate the clinical translation of GlioZERO discoveries and technologies.
Оригинален текст от CORDIS (на английски).
Участници
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaКоординаторИталия
- BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY · STANFORDСъединени щати
- BRIGHAM INC · BostonСъединени щати
- HUMANITAS MIRASOLE SPA · Rozzano (Mi)Италия
- INSTITUT CURIE · ParisФранция
- ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO · KragujevacСърбия
- NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY · KANAZAWAЯпония
- SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA · PisaИталия
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA · OaklandСъединени щати
- The University of Texas MD Anderson Cancer Center · HoustonСъединени щати
- UNIVERSITA HUMANITAS · PIEVE EMANUELEИталия
Връзки
Данни: CORDIS, © Европейски съюз